ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

US Judge Upholds Validity Of Merck's Vytorin Patent

By Peter Loftus Of DOW JONES NEWSWIRES A federal judge has upheld the validity of a U.S. patent covering Merck & Co.'s (MRK) Vytorin cholesterol-lowering drug, which could stave off competing generic copies for several years. In an opinion released Friday, U.S. District Judge Jose Linares in federal court in Newark, N.J., said a patent for Vytorin was valid and enforceable. Merck, based in Whitehouse Station, N.J., said in a recent regulatory filing it expects its U.S. exclusivity for Vytorin and a related drug, Zetia, to expire in April 2017. Mylan Inc. (MYL) had applied for U.S. Food and Drug Administration approval to sell a generic version of Vytorin before its patent protection expired, arguing that the patent was invalid and unenforceable. Schering-Plough, which was acquired by Merck in 2009, filed a patent-infringement lawsuit against Mylan in late 2009, seeking to block Mylan's product. A trial was held in December 2011, leading to Judge Linares's opinion Friday. On a conference call with analysts Friday morning, Merck Chief Executive Kenneth Frazier said he was anticipating a favorable decision. "We believe this is a patent that is valid and enforceable," he said. A Mylan spokeswoman couldn't immediately be reached. Earlier Friday, Merck reported first-quarter Vytorin sales of $444 million and Zetia sales of $614 million. Merck previously reached a settlement of patent litigation for Zetia with generics manufacturer Glenmark Pharmaceuticals. The pact will allow Glenmark to sell generic Zetia in December 2016, subject to final regulatory approval. -By Peter Loftus, Dow Jones Newswires; +1-215-982-5581;

Stock News for Merck (MRK)
10/25/201609:39:00Stocks Lifted by Upbeat Data, Earnings
10/25/201608:35:00Stocks Lifted by Upbeat Data, Earnings -- 2nd Update
10/25/201608:20:00Merck Profit Rises on Cancer Drugs, Vaccines
10/25/201608:13:00Merck Revenue and Profit Rise on Cancer Drugs, Vaccines
10/25/201606:50:52Current Report Filing (8-k)
10/25/201606:45:00Merck Announces Third-Quarter 2016 Financial Results
10/24/201621:40:00Merck Drug Gets FDA Approval as a First-Line Lung Cancer Treatment
10/24/201620:50:00Merck Drug Gets FDA Approval as a First-Line Lung Cancer Treatment
10/24/201618:04:00FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Metastatic NS...
10/21/201621:57:00FDA Approves Merck’s ZINPLAVA™ (bezlotoxumab) to Reduce Recurrence of...
10/21/201606:45:00Merck’s KEYNOTE-045 Studying KEYTRUDA® (pembrolizumab) in Ad...
10/19/201607:00:00Merck Announces Pivotal Phase 3 Study of Letermovir, an Investigational...
10/17/201617:00:00Merck Research Laboratories Facilities Designated as “Milestones i...
10/14/201608:30:00Merck Launches Biosimilars Clarified, a New Online Educational...
10/10/201602:49:00Merck Announces Recipients of Third Annual €1 Million 'Grant f...
10/09/201602:44:00Study May Boost Use of Merck Lung-Cancer Drug
10/09/201602:16:00Two Major Studies to Be Presented at ESMO 2016 Congress Presidential...
10/09/201602:15:00KEYTRUDA® (pembrolizumab) Showed Continued Overall Survival...
10/08/201608:45:00Merck Announces Longer-Term Follow-Up of Overall Survival Data...
10/08/201602:15:00New KEYTRUDA® (pembrolizumab) Data in Advanced Urothelial Cancer...

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations